hMLH_1、hMSH_2在原发性肝癌中的表达及其临床意义

The Expression of hMLH_1, hMSH_2 in Hepatocellular Carcinoma and Its Clinical Significance

目的研究hMLH1、hMSH2在原发性肝癌组织中的表达及与临床病理特征的关系。方法应用SABC免疫组化法,检测hMLH1、hMSH2在37例原发性肝癌组织中的表达。结果hMLH1、hMSH2在癌组织中的阳性率及其评分分别为48.7%(1.65±1.70)分、59.5%(2.30±1.96)分,明显低于癌旁组织83.8%(3.30±1.37)分、86.5%(4.30±2.01)分及正常肝组织88.2%(3.88±1.98)分、82.3%(4.29±1.83)分(P<0.01);hMLH1、hMSH2的表达与原发性肝癌组织分化程度有关,hMLH1的表达与AFP是否阳性有关,二者与其它临床病理特征无关。结论hMLH1、hMSH2在原发性肝癌组织发生发展中起重要抑制作用。hMLH1、hMSH2可作为预测原发性肝癌组织预后的重要指标-。

Objective To study the expression of hMLH1, hMSH2 and their association with clinico-pathological characteristics in hepatocellular carcinoma(HCC). Methods The expression of hMLH1 and hMSH2 in 37 HCC tissues was detected by SABC immunohistochemistry. Results The positive rate (score) of hMLH1 and hMSH2 expression in HCC was 48.7%(1.65±1.70) and 59.5%(2.30±1.96), respectively, which was obviously lower than that in the adjancent tumor tissues with 83.8%(3.30±1.37), and 86.5%(4.30±2.01), and in the normal liver tissues with 88.2%(3.88±1.98) and 82.3%(4.29±1.83), respectively(P<0.01). The expression of hMLH1 and hMSH2 was associated with differentiation degree of HCC, and not associated with the other clinico-pathological parameters of HCC. Conclusion The down-regulation of hMLH1 and hMSH2 may play an important role in the pathogenesis of hepatocellular carcinoma. hMLH1 and hMSH2 may serve as indices for predicting HCC prognosis.